Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors
European Journal of Nuclear Medicine and Molecular Imaging · 2025-05 · 52 (6) · 2096-2106
DOI: 10.1007/s00259-024-07058-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 14.01.2025. Verfasst von Hyehyun Jeong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Positron Emission Tomography Computed Tomography, Cyclin-Dependent Kinase 6. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Korea Health Industry Development Institute.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea.
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. jaeho.jeong@amc.seoul.kr.
- Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea. hswon87@naver.com.
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Sangwon Han
Förderung
- Korea Health Industry Development Institute
Zitieren
APA
Jeong, H., Ryu, J., Jeong, J. H., Han, S., Hyung, J., Ahn, J. H., Jung, K. H., Kim, S. B., Jeong, B. K., Lee, H. J., Gong, G., & Moon, D. H. (2025). Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors. European Journal of Nuclear Medicine and Molecular Imaging, 52(6), 2096-2106. https://doi.org/10.1007/s00259-024-07058-1
Vancouver
Jeong H, Ryu J, Jeong JH, Han S, Hyung J, Ahn JH, et al. Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(6):2096-2106. doi:10.1007/s00259-024-07058-1
BibTeX
@article{Jeong2025,
author = {Jeong, Hyehyun and Ryu, Jeongryul and Jeong, Jae Ho and Han, Sangwon and Hyung, Jaewon and Ahn, Jin-Hee and Jung, Kyung Hae and Kim, Sung-Bae and Jeong, Byung-Kwan and Lee, Hee Jin and Gong, Gyungyub and Moon, Dae Hyuk},
title = {Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
volume = {52},
number = {6},
pages = {2096--2106},
doi = {10.1007/s00259-024-07058-1}
}
EUVIMED